



## **CVRx Announces Increased Inpatient Payment for Barostim Procedure**

August 2, 2024

MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- [CVRx, Inc.](#) (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure for the inpatient setting as part of the Fiscal Year (FY) 2025 Medicare Hospital Inpatient Prospective Payment System (IPPS) final rule.

In FY 2024, Barostim was assigned to MS-DRGs 252, 253, 254 with a national average payment range of \$17,000-\$23,000. For FY 2025, Barostim will be reassigned to MS-DRG 276, which carries a national average payment of approximately \$43,000. The new payment takes effect Oct. 1, 2024.

"We applaud CMS' consideration and recognition of the resource requirements associated with the Barostim implant procedure. We believe that reassignment to MS-DRG 276 will facilitate increased access to the therapy for patients with heart failure by establishing sufficient reimbursement for the procedure when performed in an inpatient setting," said Kevin Hykes, President and CEO of CVRx.

### **About CVRx, Inc.**

CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit [www.cvr.com](http://www.cvr.com).

### **Media Contact:**

Laura O'Neill  
Finn Partners 917.497.2867  
[laura.oneill@finnpartners.com](mailto:laura.oneill@finnpartners.com)

### **Investor Contact:**

Mark Klausner or Mike Vallie  
ICR Westwicke  
443.213.0501  
[ir@cvrx.com](mailto:ir@cvrx.com)